On Monday, Stryker got an upgrade to its Relative Strength (RS) Rating, from 68 to 71.
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
Decades of market research shows that the top-performing stocks tend to have an RS Rating north of 80 as they begin their biggest price moves. See if Stryker can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Stryker is trying to complete a flat base with a 406.19 buy point. See if it can break out in heavy trading.
Stryker showed 16% EPS growth in the latest quarterly report, while sales growth came in at 11%.
The company holds the No. 9 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
